Anti-CCR5 (Leronlimab), Humanized Antibody

Anti-CCR5 (Leronlimab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is an investigational humanized IgG4 monoclonal antibody that specifically inhibits CCR5. CCR5 is a chemokine receptor that is expressed on the surface of a broad range of cells including T-cells, B-cells, and macrophages, and plays an important role in immune responses. Human Immunodeficiency Virus 1 (HIV-1) uses CCR5 as a co-receptor to enter and infect immunologic cells. The antibody binds to the hydrophilic extracellular domains of the CCR5 and competitively inhibits the CCR5-mediated HIV-1 entry into the host cells. The antibody does not target viruses using CXCR4 as a receptor to enter host cells. The original drug was granted Fast Track Designation by the US FDA to treat HIV infected patients in combination with HAART, and for metastatic triple-negative breast cancer. Currently, the drug is in early clinical trials to treat COVID-19 disease.

Immunogen Sequence:Human CCR5

Target Alternative Name:PA14, PRO 140, PRO-140, PRO140, HuPRO-140, CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5

Species Reactivities:Human

Tag Line:The biosimilar is an investigational humanized monoclonal antibody that targets CCR5, a cellular receptor that plays an important role in HIV infection, metastasis of the tumors and other diseases, including NASH

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.